Pharma Focus America

27/08/2026

𝐑𝐢𝐬𝐞 𝐨𝐟 𝐀𝐈/𝐌𝐋-𝐏𝐨𝐰𝐞𝐫𝐞𝐝 𝐀𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐨𝐫𝐬 𝐢𝐧 𝐏𝐡𝐚𝐫𝐦𝐚 𝐒𝐞𝐜𝐮𝐫𝐞 𝐒𝐮𝐩𝐩𝐥𝐲 𝐂𝐡𝐚𝐢𝐧𝐬

In Pharma Focus America – Issue 07, 𝐌𝐚𝐧𝐢𝐬𝐡 𝐆𝐚𝐫𝐠, 𝐏𝐫𝐢𝐧𝐜𝐢𝐩𝐚𝐥 𝐄𝐧𝐠𝐢𝐧𝐞𝐞𝐫, 𝐀𝐬𝐬𝐨𝐜𝐢𝐚𝐭𝐞 𝐃𝐢𝐫𝐞𝐜𝐭𝐨𝐫, 𝐇𝐢𝐤𝐦𝐚 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬, explores how Artificial Intelligence and Machine Learning are transforming pharmaceutical supply chain security — from predictive analytics and real-time monitoring to intelligent traceability and proactive risk management.

As pharmaceutical supply chains become increasingly complex, AI/ML-powered solutions are helping organisations move beyond compliance-focused serialisation toward smarter, more resilient, and proactive supply chain operations — strengthening visibility, efficiency, quality, and patient safety.

𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:
• How AI/ML can prevent supply chain errors before they occur
• The role of predictive analytics in identifying equipment and logistics failures
• AI-powered traceability for real-time end-to-end supply chain visibility
• How AI accelerates root cause analysis and deviation investigations
• Intelligent recommendations and automated corrective actions
• Real-time GxP compliance monitoring and audit readiness
• AI-enabled serialisation for counterfeit detection and product verification
• Dynamic route optimisation and proactive temperature excursion prevention
• The importance of open standards, validation, and human oversight

𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬:
AI is reshaping pharmaceutical supply chains from reactive problem-solving to proactive intelligence. By combining serialisation, traceability, IoT data, predictive analytics, and AI-driven decision support, manufacturers can build more secure and resilient supply networks while keeping 𝐩𝐫𝐨𝐝𝐮𝐜𝐭 𝐪𝐮𝐚𝐥𝐢𝐭𝐲, 𝐫𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐜𝐨𝐦𝐩𝐥𝐢𝐚𝐧𝐜𝐞, 𝐚𝐧𝐝 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐬𝐚𝐟𝐞𝐭𝐲 at the center.

🔗 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞:
https://www.pharmafocusamerica.com/information-technology/rise-of-aiml-powered-accelerators

📖 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 – 𝐈𝐬𝐬𝐮𝐞 𝟎𝟕:
https://www.pharmafocusamerica.com/latest-ebook

Discover how AI/ML-powered accelerators strengthen pharma supply chain security—reduce risk, boost compliance. Get the solution now.

26/08/2026

𝐁𝐫𝐢𝐝𝐠𝐢𝐧𝐠 𝐃𝐫𝐮𝐠 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐆𝐌𝐏 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐢𝐧 𝐁𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚

Moving from drug development into GMP manufacturing is a critical step in advancing clinical programmes. Yet gaps in communication, technical knowledge transfer, and operational coordination can create challenges for teams preparing products for clinical production.

𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:
• Connecting development and GMP manufacturing teams
• Strengthening technical knowledge transfer
• Improving cross-functional communication and handoffs
• Identifying potential bottlenecks before clinical production
• Building greater manufacturing and operational readiness
• Supporting more efficient clinical manufacturing programmes

𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬:
As biopharma pipelines continue to advance toward clinical development, the ability to efficiently translate development knowledge into GMP manufacturing becomes increasingly important. Stronger collaboration between teams can help organisations build a more predictable and scalable manufacturing pathway.

🔗 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐖𝐡𝐢𝐭𝐞 𝐏𝐚𝐩𝐞𝐫:
https://www.pharmafocusamerica.com/promotions/bend-bioscience-development-gmp-gap-whitepaper

26/08/2026

𝐓𝐡𝐞 𝟏𝟔𝐭𝐡 𝐀𝐦𝐞𝐫𝐢𝐜𝐚𝐧 𝐃𝐫𝐮𝐠 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 & 𝐅𝐨𝐫𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐒𝐮𝐦𝐦𝐢𝐭 𝐈𝐬 𝐉𝐮𝐬𝐭 𝐖𝐞𝐞𝐤𝐬 𝐀𝐰𝐚𝐲!

The 16th American Drug Delivery & Formulation Summit is taking place on 𝐒𝐞𝐩𝐭𝐞𝐦𝐛𝐞𝐫 𝟏𝟒–𝟏𝟓, 𝟐𝟎𝟐𝟔, in 𝐁𝐨𝐬𝐭𝐨𝐧 — bringing together industry experts to explore the latest developments across drug delivery, formulation, biologics, device development, and pharmaceutical technology.

𝐖𝐡𝐚𝐭 𝐘𝐨𝐮’𝐥𝐥 𝐄𝐱𝐩𝐥𝐨𝐫𝐞:
• Device development and combination product control strategies
• AI applications in pharmaceutical development
• Small-molecule drug delivery and formulation
• Biologics drug product formulation
• Novel and targeted drug delivery technologies
• Emerging challenges and innovations across the industry
• Opportunities to present research through the Poster Competition

𝐅𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐒𝐩𝐞𝐚𝐤𝐞𝐫𝐬 𝐈𝐧𝐜𝐥𝐮𝐝𝐞:
• Ning Yu, Ph.D., MBA — BioCryst Pharmaceuticals
• Jimmy Chen — Shionogi Inc.
• Srini Sridharan — Bristol Myers Squibb
• Theresa Scheuble — Johnson & Johnson Innovative Medicine

𝐄𝐱𝐜𝐥𝐮𝐬𝐢𝐯𝐞 𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐒𝐚𝐯𝐢𝐧𝐠:
Pharma Focus subscribers can save 𝐀𝐦𝐞𝐫𝐢𝐜𝐚𝐧 $𝟐𝟎𝟎 on their registration with code: 𝐏𝐅-𝟏𝟐𝟗𝟓.

🔗 𝐒𝐞𝐜𝐮𝐫𝐞 𝐘𝐨𝐮𝐫 𝐏𝐥𝐚𝐜𝐞:
https://industry.pharmafocusamerica.com/clientemailblast/1787556237-American-DDF-Summit.html

𝐃𝐚𝐭𝐞: September 14–15, 2026
𝐋𝐨𝐜𝐚𝐭𝐢𝐨𝐧: Boston, USA

26/08/2026

𝐒𝐢𝐦𝐩𝐥𝐢𝐟𝐲 𝐋𝐚𝐛-𝐒𝐜𝐚𝐥𝐞 𝐂𝐨𝐧𝐜𝐞𝐧𝐭𝐫𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐁𝐮𝐟𝐟𝐞𝐫 𝐄𝐱𝐜𝐡𝐚𝐧𝐠𝐞 𝐰𝐢𝐭𝐡 𝐓𝐅𝐅

Tangential Flow Filtration (TFF) is widely used for separating and purifying biomolecules across immunology, protein chemistry, molecular biology, biochemistry, and microbiology.

Cytiva introduces the 𝐌𝐢𝐧𝐢𝐦𝐚𝐭𝐞™ 𝐓𝐚𝐧𝐠𝐞𝐧𝐭𝐢𝐚𝐥 𝐅𝐥𝐨𝐰 𝐅𝐢𝐥𝐭𝐫𝐚𝐭𝐢𝐨𝐧 𝐒𝐲𝐬𝐭𝐞𝐦, designed to simplify laboratory-scale concentration, desalting, and buffer exchange processes.

𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:
• Simplified TFF for laboratory-scale applications
• Supports concentration, desalting, and buffer exchange
• Suitable for sample volumes from 10 mL to thousands of liters
• Applicable across a broad range of biomolecule research workflows
• Designed to provide practical guidance and support for laboratory users

𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬:
Efficient biomolecule separation and purification are essential across research and bioprocessing workflows. A flexible TFF solution can help researchers streamline key processing steps while supporting scalable applications.

🔗 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫 𝐭𝐡𝐞 𝐌𝐢𝐧𝐢𝐦𝐚𝐭𝐞™ 𝐓𝐅𝐅 𝐒𝐲𝐬𝐭𝐞𝐦:
https://industry.pharmafocusamerica.com/clientemailblast/1787561328-Cytiva-TFF.html

26/08/2026

𝐀𝐈 𝐈𝐬 𝐑𝐞𝐬𝐡𝐚𝐩𝐢𝐧𝐠 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠

In Pharma Focus America – Issue 07, 𝐂𝐚𝐫𝐥 𝐏𝐚𝐭𝐭𝐞𝐫𝐬𝐨𝐧, 𝐃𝐢𝐫𝐞𝐜𝐭𝐨𝐫 𝐨𝐟 𝐐𝐮𝐚𝐥𝐢𝐭𝐲, 𝐋𝐀𝐓𝐈𝐓𝐔𝐃𝐄 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥𝐬 𝐈𝐧𝐜., explores how Artificial Intelligence is transforming pharmaceutical manufacturing operations — from real-time quality control and predictive maintenance to continuous process optimisation.

As AI adoption accelerates, manufacturers are finding new ways to improve efficiency, reduce waste, strengthen quality, and move products to market faster, while maintaining rigorous regulatory standards and human oversight.

𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:
• How AI and Process Analytical Technology are enabling real-time quality monitoring
• The shift from batch processing toward continuous manufacturing
• AI’s role in predictive maintenance and equipment optimisation
• How digital twins can support process design, scale-up, and technology transfer
• The potential of AI-enabled Real-Time Release Testing
• Regulatory considerations and the importance of human-in-the-loop oversight
• Challenges around data quality, legacy systems, validation, and implementation

𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬:
AI in pharmaceutical manufacturing is about more than automation. It is creating opportunities to build smarter, more responsive, and more efficient manufacturing systems — while keeping 𝐩𝐫𝐨𝐝𝐮𝐜𝐭 𝐪𝐮𝐚𝐥𝐢𝐭𝐲, 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 𝐬𝐚𝐟𝐞𝐭𝐲, 𝐚𝐧𝐝 𝐡𝐮𝐦𝐚𝐧 𝐣𝐮𝐝𝐠𝐦𝐞𝐧𝐭 at the center.

🔗 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞:
https://www.pharmafocusamerica.com/information-technology/ai-in-pharmaceutical-manufacturing

📖 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 – 𝐈𝐬𝐬𝐮𝐞 𝟎𝟕:
https://www.pharmafocusamerica.com/latest-ebook

Discover how AI transforms pharmaceutical manufacturing operations—boost quality, cut costs, and accelerate time-to-market. Get the insights now!

25/08/2026

𝐑𝐞𝐝𝐞𝐟𝐢𝐧𝐢𝐧𝐠 𝐑𝐍𝐀 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐓𝐡𝐫𝐨𝐮𝐠𝐡 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐁𝐢𝐨𝐜𝐚𝐭𝐚𝐥𝐲𝐬𝐢𝐬

RNA therapeutics are rapidly moving from scientific innovation to mainstream medicine, creating unprecedented demands on manufacturing. As therapeutic applications expand to larger patient populations, traditional solid-phase oligonucleotide synthesis (SPOS) faces growing challenges around scalability, yield, impurities, solvent use, and sustainability.

In Pharma Focus America – Issue 07, 𝐃𝐫. 𝐒𝐭𝐞𝐟𝐚𝐧 𝐋𝐮𝐭𝐳, 𝐂𝐡𝐢𝐞𝐟 𝐒𝐜𝐢𝐞𝐧𝐭𝐢𝐟𝐢𝐜 𝐎𝐟𝐟𝐢𝐜𝐞𝐫, 𝐂𝐨𝐝𝐞𝐱𝐢𝐬, explores how enzyme engineering and biocatalysis are opening new pathways for scalable, efficient, and sustainable RNA manufacturing. He highlights the potential of engineered enzymes and ligase-based assembly to overcome limitations of conventional chemistry and support the next generation of RNA therapeutics.

𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:
• The growing manufacturing demand driven by the expansion of RNA therapeutics
• Why traditional SPOS faces challenges in high-volume RNA production
• Yield loss, impurities, and purification challenges in chemical synthesis
• The environmental and infrastructure burden of solvent-intensive manufacturing
• How enzyme-enabled synthesis can provide scalable and sustainable alternatives
• The role of engineered ligases in full-length RNA assembly
• Modular ligation strategies for improving yield and product quality
• Advances in engineered enzymes for modified RNA production
• The transition of enzymatic manufacturing from laboratory to pilot-scale operations
• How biocatalysis could reshape the future of large-scale RNA manufacturing

𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬:
The rapid expansion of RNA therapeutics is creating a manufacturing challenge that traditional production approaches may not be equipped to address at scale. As therapies move beyond rare diseases toward indications affecting millions of patients, manufacturing must become more efficient, scalable, and sustainable.

For pharmaceutical and biotechnology organisations, the next phase of RNA medicine will depend not only on discovering innovative therapies, but also on developing manufacturing platforms capable of delivering them reliably and sustainably at scale.

🔗 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞:
https://www.pharmafocusamerica.com/manufacturing/redefining-rna-manufacturing-through-innovation

📖 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 – 𝐈𝐬𝐬𝐮𝐞 𝟎𝟕:
https://www.pharmafocusamerica.com/latest-ebook

Redefine RNA manufacturing with innovative biocatalysis. Boost yields, cut costs, and accelerate timelines—get the full insights now.

25/08/2026

𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐂𝐚𝐩𝐚𝐜𝐢𝐭𝐲 𝐏𝐥𝐚𝐧𝐧𝐢𝐧𝐠 𝐟𝐨𝐫 𝐁𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐚𝐧𝐝 𝐍𝐞𝐱𝐭-𝐆𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬

For biologics and next-generation therapies, capacity planning is no longer simply about forecasting future demand. With long development timelines, evolving modalities and significant capital commitments, pharmaceutical leaders need a more flexible approach to managing capacity risk.

𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:
• Why traditional biologics capacity planning models are becoming less effective
• How rising titres, single-use technologies and CMOs are changing capacity strategies
• Why cell and gene therapies require a shift from scale-up to scale-out thinking
• How pharma leaders can balance build, buy and borrow capacity options
• The growing importance of flexibility and reversibility in capacity investments
• Why domestic manufacturing and supply resilience are becoming strategic considerations

𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬:
Capacity decisions made years before demand becomes clear can expose pharmaceutical companies to significant stranded capital and underutilised assets.

A smarter strategy is to build flexibility into the portfolio—combining owned capacity, external manufacturing and staged commitments tied to clinical and commercial milestones. For next-generation therapeutics, the goal is not to predict demand perfectly, but to stay flexible when those predictions change.

🔗 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞:
https://www.pharmafocusamerica.com/articles/strategic-capacity-planning-for-biologics

&D

Biologics capacity planning helps pharma leaders balance build, buy and borrow strategies, workforce constraints, manufacturing flexibility and supply resilience.

25/08/2026

𝐀𝐈-𝐏𝐨𝐰𝐞𝐫𝐞𝐝 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐃𝐚𝐭𝐚 𝐌𝐚𝐧𝐚𝐠𝐞𝐦𝐞𝐧𝐭: 𝐈𝐦𝐩𝐫𝐨𝐯𝐢𝐧𝐠 𝐐𝐮𝐚𝐥𝐢𝐭𝐲, 𝐒𝐩𝐞𝐞𝐝, 𝐚𝐧𝐝 𝐑𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐂𝐨𝐦𝐩𝐥𝐢𝐚𝐧𝐜𝐞

Clinical trial data is growing more complex, while sponsors face increasing pressure to improve data quality, accelerate database lock, and meet evolving regulatory expectations. AI-powered clinical data management is emerging as a way to address all three.

𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:
• Why growing clinical data volumes have made traditional data management increasingly difficult to scale
• How ICH E6(R3) is reshaping expectations around quality by design, risk management and data traceability
• How continuous AI-powered surveillance can identify data issues earlier and reduce unnecessary queries
• Why AI can help compress the time between last patient visit and database lock
• How sponsors can make AI models defensible under Part 11 and FDA credibility expectations
• Lessons from an AI-enabled clinical data management transformation
• Five questions pharmaceutical leadership should ask before investing in AI

𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬:
AI in clinical data management is moving beyond experimentation. As data sources multiply and regulatory expectations evolve, sponsors need approaches that improve quality without increasing operational burden.

The opportunity is not simply to automate the work of clinical data managers. It is to shift their focus from manual data cleaning toward risk assessment, oversight and higher-value clinical judgment.

🔗 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞:
https://www.pharmafocusamerica.com/articles/ai-powered-clinical-data-management-improving

&D

AI-powered clinical data management improves data quality, speeds database lock, and supports FDA, ICH E6(R3), Part 11, and GxP compliance for pharma sponsors.

24/08/2026

𝐆𝐋𝐏-𝟏 𝐚𝐭 𝐒𝐜𝐚𝐥𝐞: 𝐖𝐡𝐲 𝟐𝟎𝟐𝟔 𝐖𝐢𝐥𝐥 𝐑𝐞𝐰𝐚𝐫𝐝 𝐎𝐫𝐜𝐡𝐞𝐬𝐭𝐫𝐚𝐭𝐨𝐫𝐬, 𝐍𝐨𝐭 𝐂𝐚𝐩𝐚𝐜𝐢𝐭𝐲 𝐁𝐮𝐢𝐥𝐝𝐞𝐫𝐬

The GLP-1 boom has transformed the U.S. pharmaceutical landscape—but as demand continues to accelerate, the challenge is no longer simply about adding manufacturing capacity.

In Pharma Focus America – Issue 07, Dr. Stefan Kahl, Director, BearingPoint, explores why the next phase of GLP-1 growth will be defined by end-to-end orchestration, integrating API, sterile fill-finish, devices, assembly, quality, and sustainability into a resilient operating model.

𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:
• Why GLP-1 bottlenecks are shifting from API production to fill-finish, devices and assembly
• The emerging “bottleneck triangle” of sterile fill-finish, primary packaging and device platforms
• Why device selection has become a strategic product-architecture decision
• How vertical integration is reshaping the U.S. CDMO capacity market
• Why quality and regulatory readiness are becoming competitive advantages
• The growing role of sustainability in GLP-1 process and device design
• How end-to-end “control tower” models can reduce supply-chain volatility
• Why oral GLP-1 therapies may relocate—not eliminate—supply-chain complexity
• What pharma leaders should do now to build resilient GLP-1 operating models

𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬:
GLP-1 scale-up is revealing a fundamental shift in pharmaceutical manufacturing: capacity alone does not create resilience. Integration does.

As constraints move downstream, organisations that synchronise API, fill-finish, devices, assembly, quality, and supply planning will be better positioned to scale reliably under pressure.

🔗 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞:
https://www.pharmafocusamerica.com/research-development/glp-1-at-scale-why-2026-will-reward

📖 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐀𝐦𝐞𝐫𝐢𝐜𝐚 – 𝐈𝐬𝐬𝐮𝐞 𝟎𝟕:
https://www.pharmafocusamerica.com/e-book

22/08/2026

𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐓𝐰𝐢𝐧𝐬 𝐢𝐧 𝐏𝐡𝐚𝐫𝐦𝐚 𝐌𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠: 𝐎𝐩𝐭𝐢𝐦𝐢𝐳𝐢𝐧𝐠 𝐏𝐫𝐨𝐜𝐞𝐬𝐬 𝐏𝐞𝐫𝐟𝐨𝐫𝐦𝐚𝐧𝐜𝐞

Digital twins are moving beyond pilot projects to become an important part of modern pharmaceutical manufacturing. By connecting live process data with predictive models, digital twins can help manufacturers improve process performance, optimize technology transfer, strengthen quality, and make better use of existing assets.

𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:
• Understanding what makes a digital twin different from a conventional dashboard
• Exploring the three tiers of digital twin maturity
• Using digital twins for virtual scale-up and technology transfer
• Applying soft sensors for real-time quality insights
• Improving yield, consistency, asset availability and changeover performance
• Understanding validation, model drift and data integrity requirements
• Evaluating the business case and long-term ownership of digital twins

𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬:
As pharmaceutical manufacturers face increasing pressure to improve efficiency, quality and capacity without relying solely on new capital investment, digital twins can provide a powerful way to turn process data into actionable insights. A well-designed and properly governed digital twin can help transform process understanding into a lasting operational asset.

🔗 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞:
https://www.pharmafocusamerica.com/articles/digital-twins-in-pharma-manufacturing